Donald Gray Heppner Jr., MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

None Reported

None Reported

First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers.
Vaccine
Volume: 31
Date: 10 2013
www.ncbi.nlm.nih.gov/pubmed/24029408

Current strategic thinking for the development of a trivalent alphavirus vaccine for human use.
Am J Trop Med Hyg
Volume: 91
Date: 09 2014
www.ncbi.nlm.nih.gov/pubmed/24842880

Safety and comparability of controlled human Plasmodium falciparum infection by mosquito bite in malaria-naïve subjects at a new facility for sporozoite challenge.
PLoS One
Volume: 9
Date: 11 2014
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236046/

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
New England Journal of Medicine
Volume: 376
Date: 01 2017
www.ncbi.nlm.nih.gov/pmc/articles/PMC5408576/

Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine.
PLoS One
Volume: 12
Date: 03 2017
www.ncbi.nlm.nih.gov/pmc/articles/PMC5345808/

Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.
Canadian Medical Association Journal
Volume: 189
Date: 06 2017
www.ncbi.nlm.nih.gov/pmc/articles/PMC5478408/pdf/189e819.pdf

Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic.
Vaccine
Volume: 35
Date: 08 2017
www.ncbi.nlm.nih.gov/pubmed/28647166

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Lancet Inf Disease
Volume: 17
Date: 08 2017
www.thelancet.com/pdfs/journals/laninf/PIIS1473-3099(17)30313-4.pdf

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment.
Vaccine X
Volume: 207
Date: 01 2019
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668225/

A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants
Journal Clinical Investigation
6;132(10):e157707
Date: 05 2022
https://pubmed.ncbi.nlm.nih.gov/35316221/